Key Points
- CFO Deborah Kaster bought 15,000 shares of Adagio Medical on Dec. 16 at an average price of $1.20 per share for a total of $18,000, creating a new direct position (disclosed in an SEC Form 4).
- Adagio Medical is a small, unprofitable company with a market cap of about $14.46M, recent EPS of ($0.66), weak liquidity (quick ratio 0.68, current ratio 0.84) and a 52‑week range of $0.63–$2.87; shares opened at $0.94 on the latest trading day.
- Institutional investors own about 48.08% of the stock (notably Perceptive Advisors), while analyst coverage is mixed—Lake Street has a buy rating with a $4 target, Weiss Ratings maintains a sell, and the consensus is "Hold" with an average $4 price target.
Adagio Medical Holdings, Inc. (NASDAQ:ADGM - Get Free Report) CFO Deborah Kaster bought 15,000 shares of the stock in a transaction on Tuesday, December 16th. The shares were bought at an average price of $1.20 per share, for a total transaction of $18,000.00. Following the purchase, the chief financial officer directly owned 15,000 shares in the company, valued at approximately $18,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Adagio Medical Stock Performance
Shares of NASDAQ ADGM opened at $0.94 on Friday. The firm's 50-day moving average price is $1.07 and its 200-day moving average price is $1.36. Adagio Medical Holdings, Inc. has a 52-week low of $0.63 and a 52-week high of $2.87. The company has a market cap of $14.46 million, a PE ratio of -0.62 and a beta of 0.16. The company has a quick ratio of 0.68, a current ratio of 0.84 and a debt-to-equity ratio of 1.96.
Adagio Medical (NASDAQ:ADGM - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.66) earnings per share for the quarter.
Hedge Funds Weigh In On Adagio Medical
Institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC lifted its position in Adagio Medical by 0.7% during the second quarter. Perceptive Advisors LLC now owns 9,876,576 shares of the company's stock valued at $12,840,000 after purchasing an additional 64,157 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Adagio Medical by 17.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 821,261 shares of the company's stock worth $1,068,000 after buying an additional 121,261 shares during the period. Finally, Cresset Asset Management LLC purchased a new position in shares of Adagio Medical during the 2nd quarter valued at about $39,000. 48.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. Lake Street Capital began coverage on Adagio Medical in a report on Tuesday, December 2nd. They set a "buy" rating and a $4.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adagio Medical in a research report on Monday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $4.00.
View Our Latest Research Report on ADGM
Adagio Medical Company Profile
(
Get Free Report)
Adagio Medical Holdings, Inc, a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
